The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer
Abstract
INTRODUCTION: Nanocarriers have emerged as a powerful alternative for cancer therapy. Indeed, they are promising candidates to tackle the acquired resistance of surviving cells against antiproliferative drugs - the so-called multidrug resistance (MDR) phenomenon - which has arisen as one of the major clinical issues of chemotherapy. Among nanocarriers, this review focuses on the recent approaches based on tailored mesoporous silica nanoparticles (MSNs) that could overcome this problem. Areas covered: Herein we summarize the current efforts developed to provide MSN-based nanosystems of enhanced dual therapeutic action against diseased cells. This can be accomplished by three main approaches: i) increasing nanosystems' killing capability towards particular cells by enhancing both recognition and specificity; ii) increasing the apoptotic effect throughout co-delivery of several drugs; or iii) combining drug delivery with apoptosis induced by physical methods. Expert opinion: The development of multifunctional nanosystems able to exert the optimal therapeutic action through the minimal administration constitutes a major challenge in nanomedicine. Recent developments in advanced MSN-based platforms for drug delivery represent promising avenues in the management of MDR associated with cancer therapy. All strategies discussed in this manuscript demonstrate improvements against difficult-to-treat tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Reproducibility crisis: Blame it on the antibodies
Baker, M. (2015) · Nature · doi:10.1038/521274a · Cited by 830
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Co-delivery of chemotherapeutics and proteins for synergistic therapy
He, C., Tang, Z., Tian, H., & Chen, X. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.021 · Cited by 231
Duan, J., Mansour, H. M., Zhang, Y., Deng, X., Chen, Y., Wang, J., Pan, Y., & Zhao, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.01.020 · Cited by 194
Cited by
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights
Vallet-Regí, M., Colilla, M., Izquierdo-Barba, I., & Manzano, M. (2017) · Molecules · doi:10.3390/molecules23010047 · Cited by 538
Self-citationLi, Z., Zhang, Y., & Feng, N. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1575806 · Cited by 321
Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment
Martínez-Carmona, M., Lozano, D., Colilla, M., & Vallet-Regí, M. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.11.007 · Cited by 220
Self-citationAdvances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update
Castillo, R. R., Lozano, D., González, B., Manzano, M., Izquierdo-Barba, I., & Vallet-Regí, M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598375 · Cited by 197
Self-citation
Metadata
- Authors
- Castillo, R. R., Colilla, M., & Vallet-Regí, M.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2016-07-25
- Volume
- 14
- Issue
- 2
- Pages
- 229-243
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2474175643
- Cited by
- 176
- References
- 11
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. https://app.cochat.ai/papers/10.1080/17425247.2016.1211637
- The paper
- Castillo, R. R., Colilla, M., & Vallet-Regí, M. (2017). Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2016.1211637
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.